|
gptkbp:instanceOf
|
gptkb:chemical_compound
investigational drug
|
|
gptkbp:abandoned_for
|
lack of efficacy
|
|
gptkbp:alsoKnownAs
|
SU5416
|
|
gptkbp:ATCCode
|
none
|
|
gptkbp:CASNumber
|
194494-44-7
|
|
gptkbp:clinicalTrialPhase
|
Phase II
|
|
gptkbp:developedBy
|
gptkb:Sugen
anti-cancer agent
|
|
gptkbp:has_KEGG_Drug_ID
|
D05813
|
|
gptkbp:hasInChIKey
|
QJQYQKZDHGJZKJ-UHFFFAOYSA-N
|
|
gptkbp:hasMolecularFormula
|
C20H16N4O
|
|
gptkbp:hasSMILES
|
Cc1cc(nc1)C=C2C=CC(=CC2)C(=O)Nc3ccccn3
|
|
gptkbp:hasUNII
|
1Y1FQ8V5SZ
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Semaxanib
|
|
gptkbp:IUPACName
|
3-[(2,4-dimethylpyrrol-5-yl)methylidenyl]-N-(2-pyridyl)benzamide
|
|
gptkbp:legalStatus
|
investigational
|
|
gptkbp:mechanismOfAction
|
VEGFR-2 tyrosine kinase inhibitor
|
|
gptkbp:molecularWeight
|
328.37 g/mol
|
|
gptkbp:PubChem_CID
|
CHEMBL19021
4470706
5311296
DB06441
|
|
gptkbp:routeOfAdministration
|
intravenous
|
|
gptkbp:studiedBy
|
gptkb:non-small_cell_lung_cancer
gptkb:glioblastoma
colorectal cancer
melanoma
solid tumors
renal cell carcinoma
|
|
gptkbp:target
|
vascular endothelial growth factor receptor 2
|
|
gptkbp:bfsParent
|
gptkb:SU5498
|
|
gptkbp:bfsLayer
|
6
|